Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment

Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity

NCT04729153 ·Status: UNKNOWN

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

NCT03549832 ·Status: COMPLETED ·Phase: NA

14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

NCT00308048 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

NCT02496078 ·Status: COMPLETED ·Phase: PHASE3

HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection

NCT02309918 ·Status: COMPLETED ·Phase: PHASE2

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

NCT02032901 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

NCT02333292 ·Status: COMPLETED

Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases

NCT06829966 ·Status: COMPLETED

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

NCT02551861 ·Status: WITHDRAWN ·Phase: PHASE2

Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA

NCT03318887 ·Status: COMPLETED

Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C

NCT02639585 ·Status: UNKNOWN ·Phase: PHASE4

Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

NCT03818308 ·Status: COMPLETED ·Phase: PHASE2

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

NCT04112303 ·Status: COMPLETED ·Phase: PHASE3

Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]

NCT03480932 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

NCT04387526 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt

NCT03510637 ·Status: UNKNOWN

An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C

NCT03423641 ·Status: COMPLETED

Effect Of DAAs For Treatment Of HCV On Normal Kidney

NCT03296930 ·Status: UNKNOWN ·Phase: PHASE4

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

NCT04382404 ·Status: COMPLETED ·Phase: PHASE1

Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

NCT03887637 ·Status: UNKNOWN

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

NCT02822794 ·Status: COMPLETED ·Phase: PHASE3

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

NCT03163849 ·Status: UNKNOWN ·Phase: PHASE3

Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse

NCT04662138 ·Status: UNKNOWN

Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

NCT03487848 ·Status: TERMINATED ·Phase: PHASE2

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

NCT02201940 ·Status: COMPLETED ·Phase: PHASE3